ONWARD Announces Participation at Upcoming Events in October
29 Septiembre 2022 - 12:30AM
Business Wire
ONWARD Medical N.V. (Euronext: ONWD), the medical technology
company creating innovative therapies to restore movement,
independence, and health in people with spinal cord injury, today
announced that management will participate in the following
upcoming events in October:
- Investors’ Day Geneva October 5, 2022
Geneva, Switzerland Dave Marver, CEO, will give a company
presentation.
- The 3rd Annual Reeve Summit October 13-14,
2022 Washington, DC USA Dave Marver will participate in
a keynote session, The Power of Partnership to Speed Cures to
Market, with Marco Baptista, Chief Scientific Officer, Christopher
& Dana Reeve Foundation.
- Oppenheimer Healthcare Showcase October 18,
2022 Palo Alto, CA USA Lara Smith Weber, CFO, will give
a company presentation and participate in 1:1 meetings.
- VFB Soirées (Flemish Federation of
Investors) October 27, 2022 Virtual event at 19:30
CET Dave Marver, CEO, will give a company presentation.
Information on upcoming conferences is available in the investor
section of the ONWARD website at
https://ir.onwd.com/news-events.
About ONWARD Medical
ONWARD is a medical technology company creating innovative
therapies to restore movement, independence, and health in people
with spinal cord injuries. ONWARD’s work builds on more than a
decade of basic science and preclinical research conducted at the
world’s leading neuroscience laboratories. ONWARD’s ARC Therapy,
which can be delivered by implantable (ARC-IM) or external (ARC-EX)
systems, is designed to deliver targeted, programmed spinal-cord
stimulation to restore movement and other functions in people with
spinal cord injury, ultimately improving their quality of life.
ONWARD has received three Breakthrough Device Designations from
the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an
external, non-invasive platform consisting of a wearable stimulator
and wireless programmer. Positive top line data were reported in
September 2022 from the company’s first pivotal study, called
Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper
extremity strength and function. The company is now preparing
marketing approval submissions for the U.S. and Europe. ARC-IM
consists of an implantable pulse generator and lead that is placed
near the spinal cord. The company completed its first-in-human use
of the ARC-IM neurostimulator in May 2022.
ONWARD is headquartered at the High Tech Campus in Eindhoven,
the Netherlands. It has substantial operations in Lausanne,
Switzerland, and a growing U.S. presence in Boston, Massachusetts.
For additional information about the company, please visit
ONWD.com. To access our 2022 Financial Calendar, please visit
IR.ONWD.com.
Disclaimer
Certain statements, beliefs, and opinions in this press release
are forward-looking, which reflect the Company or, as appropriate,
the Company directors’ current expectations and projections about
future events. By their nature, forward-looking statements involve
a number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, the Company expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220928005744/en/
For Company Enquiries: info@onwd.com For Media
Enquiries: MC Services AG US: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka, P: +49 89
210 228 0 media@onwd.com For Investor Enquiries:
investors@onwd.com